- Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
-
Yeon JE
- KMID: 2428755
- Clin Mol Hepatol.
- 2018 Sep;24(3):294-296.
- doi: 10.3350/cmh.2018.1009
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Use of sofosbuvir in chronic kidney disease: Is it necessary?
-
Lim TS, Ahn SH
- KMID: 2406037
- Clin Mol Hepatol.
- 2017 Dec;23(4):308-310.
- doi: 10.3350/cmh.2017.0109
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea
-
Cho Y, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ
- KMID: 2359817
- Clin Mol Hepatol.
- 2015 Dec;21(4):358-364.
- doi: 10.3350/cmh.2015.21.4.358
BACKGROUND/AIMS: The previous standard treatment for chronic hepatitis C (CHC) patients, comprising a combination of pegylated interferon (IFN) and ribavirin, was associated with suboptimal efficacy and severe adverse reactions. A... -
- CITED
-
- Close
- SHARE
-
- Close
- Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
-
Lee HW, Yoo KY, Won JW, Kim HJ
- KMID: 2389361
- Gut Liver.
- 2017 Sep;11(5):721-727.
- doi: 10.5009/gnl17209
BACKGROUND/AIMS: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. METHODS: Patients (n=30) were enrolled between September 2015 and April 2016. Twenty-six patients were genotype 1 (1b, n=21;... -
- CITED
-
- Close
- SHARE
-
- Close
- Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure
-
Parigi TL, Torres MC, Aghemo A
- KMID: 2467245
- Clin Mol Hepatol.
- 2019 Dec;25(4):360-365.
- doi: 10.3350/cmh.2019.0022
Despite the high efficacy of direct acting antivirals (DAAs) not all patients successfully clear hepatitis C virus infection, in fact, approximately 1–3% fail to reach a sustained virological response 12... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
-
Kim YM, Kim SB, Song IH, Lee SH, Kim HS, Lee TH, Kang YW, Kim SH, Lee BS, Chae HB, Song MJ, Jang JW, Ko SY, Lee JD
- KMID: 2428759
- Clin Mol Hepatol.
- 2018 Sep;24(3):311-318.
- doi: 10.3350/cmh.2017.0070
BACKGROUND/AIMS: Sofosbuvir plus ribavirin is a standard treatment for patients infected with chronic hepatitis C virus (HCV) genotype 2 in Korea. The purpose of this study was to examine the... -
- CITED
-
- Close
- SHARE
-
- Close
- Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients
-
Shin HP, Burman B, Kozarek RA, Zeigler A, Wang C, Lee H, Zehr T, Edwards AM, Siddique A
- KMID: 2389360
- Gut Liver.
- 2017 Sep;11(5):711-720.
- doi: 10.5009/gnl16447
BACKGROUND/AIMS: The approval of sofosbuvir (SOF), a direct-acting antiviral, has revolutionized the treatment of chronic hepatitis C virus (HCV). METHODS: We assessed the sustained virological response (SVR) of SOF-based regimens in... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function
-
Shin HP, Park JA, Burman B, Kozarek RA, Siddique A
- KMID: 2406040
- Clin Mol Hepatol.
- 2017 Dec;23(4):316-322.
- doi: 10.3350/cmh.2016.0087
BACKGROUND/AIMS: Treatment of chronic hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD) is essential. The availability of sofosbuvir (SOF) has dramatically improved overall HCV cure rates,... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of direct antiviral agent failures
-
Buti M, Esteban R
- KMID: 2373146
- Clin Mol Hepatol.
- 2016 Dec;22(4):432-438.
- doi: 10.3350/cmh.2016.0107
The current standard of care for patients with chronic hepatitis C virus (HCV) infection is a combination of direct-acting antiviral agents (DAAs). Most HCV patients treated with these drugs achieve... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection
-
Sato S, Moriya K, Furukawa M, Saikawa S, Namisaki T, Kitade M, Kawaratani H, Kaji K, Takaya H, Shimozato , Sawada Y, Seki K, Kitagawa K, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H
- KMID: 2447252
- Clin Mol Hepatol.
- 2019 Mar;25(1):65-73.
- doi: 10.3350/cmh.2018.0070
BACKGROUND/AIMS: L-carnitine not only alleviates hyperammonemia and reduces muscle cramps in patients with liver cirrhosis, but also improves anemia in patients with chronic hepatitis and renal dysfunction. This study prospectively... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C
-
de Medeiros LPJ, Lima MB, Pires MM, Maciel AM, Medeiros R, Donadel MD, Pereira IM, Leão FM, Pires LE, Rzetelna H, Brandão-Mello CE
- KMID: 2413256
- Osong Public Health Res Perspect.
- 2018 Apr;9(2):50-58.
- doi: 10.24171/j.phrp.2018.9.2.03
OBJECTIVES: To evaluate the impact of 3 treatment regimens upon health-related quality of life and work productivity using patient-reported outcomes (PROs) in chronic hepatitis C infected patients: sofosbuvir (SOF) +... -
- CITED
-
- Close
- SHARE
-
- Close
- Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3
-
Jung YK
- KMID: 2373412
- Korean J Gastroenterol.
- 2016 Mar;67(3):132-136.
- doi: 10.4166/kjg.2016.67.3.132
Ever since direct-acting antiviral agents (DAA) have been approved and released into the world, numerous studies on the efficacy, adverse effects and drug-drug interactions of interferon-free DAA combination therapy have... -
- CITED
-
- Close
- SHARE
-
- Close
- Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1
-
Park SH
- KMID: 2373411
- Korean J Gastroenterol.
- 2016 Mar;67(3):127-131.
- doi: 10.4166/kjg.2016.67.3.127
The introduction of direct-acting antiviral agents (DAAs) has markedly improved the sustained virological response (SVR) rates in patients with chronic hepatitis C. Currently, four classes of DAAs targeting three HCV... -
- CITED
-
- Close
- SHARE
-
- Close
